Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.4K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.4K
Structure and Function of Platelets01:18

Structure and Function of Platelets

4.4K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
4.4K
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

494
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
494

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessment of Commutability in Factor VIII Activity Testing Using Fresh Human Plasma Samples.

Thrombosis and haemostasis·2026
Same author

Review of laboratory methods used for analysis of von Willebrand factor and for diagnosis of related diseases.

Expert review of hematology·2025
Same author

Von Willebrand factor is a multifaceted player in hemostasis requiring a diverse array of analytical and diagnostic approaches.

Expert review of hematology·2025
Same author

Strengthening international cooperation and confidence in the field of laboratory medicine by ISO standardization.

Clinical chemistry and laboratory medicine·2025
Same author

Behind the scenes of EQA–characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part IV – Benefits for participant laboratories

Clinical chemistry and laboratory medicine·2025
Same author

Behind the scenes of EQA – characteristics, capabilities, benefits and assets of external quality assessment (EQA): Part III – EQA samples

Clinical chemistry and laboratory medicine·2025

Related Experiment Video

Updated: Mar 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K

Platelet Function Testing-Guided Antiplatelet Therapy.

Ekaterina Lenk1, Michael Spannagl2

  • 1Verum Diagnostica GmbH, Roche Professional Diagnostics , Munich, Germany.

EJIFCC
|September 30, 2016
PubMed
Summary

Platelet function testing identifies patients inadequately responding to antiplatelet drugs, enabling personalized treatment to reduce ischemic events and improve cardiovascular outcomes.

Keywords:
antiplatelet drug resistanceantiplatelet therapydrug monitoringhigh platelet reactivity (HPR)platelet function test

More Related Videos

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

881
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K

Related Experiment Videos

Last Updated: Mar 14, 2026

Microfluidics in Assessing Platelet Function
06:47

Microfluidics in Assessing Platelet Function

Published on: November 8, 2024

1.8K
Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor
06:32

Dynamic Multiparameter Platelet Function Assessment Using a Capacitive Biosensor

Published on: May 2, 2025

881
Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets
05:49

Procoagulant Platelet Characterization by Measuring Phosphatidylserine Exposure and Microvesicle Release from Human Purified Platelets

Published on: November 29, 2024

1.3K

Area of Science:

  • Cardiology
  • Vascular Biology
  • Pharmacology

Background:

  • Cardiovascular diseases are a leading cause of death, with vascular disorders increasing due to aging, lifestyle, diabetes, and dyslipidemia.
  • Platelet activation contributes to arterial thrombus formation, leading to occlusive vascular events like myocardial infarction and stroke.
  • Current antiplatelet therapies (aspirin, clopidogrel) have variable efficacy, with a subset of patients ('non-responders') facing higher ischemic risks.

Purpose of the Study:

  • To evaluate the clinical utility of platelet function (PF) testing in optimizing antiplatelet therapy.
  • To determine if personalized antiplatelet strategies guided by PF tests improve patient outcomes and safety.
  • To address the challenges posed by non-response to standard antiplatelet treatments and the limitations of newer agents.

Main Methods:

  • Review of evidence from randomized studies and recent research on tailored antiplatelet therapies.
  • Analysis of the role of platelet function diagnostics in identifying patient subgroups.
  • Consideration of cost-effectiveness and bleeding risk associated with different antiplatelet agents and testing strategies.

Main Results:

  • Platelet function testing can identify patients with inadequate response to antiplatelet therapy, who are at increased risk for ischemic complications.
  • Tailored antiplatelet strategies, guided by PF diagnostics, have shown association with improved patient outcomes.
  • Despite initial uncertainty from randomized trials, a consensus expert opinion now supports the clinical adoption of PF diagnostics.

Conclusions:

  • Platelet function testing is valuable for personalizing antiplatelet therapy, enhancing efficacy, and improving patient safety.
  • PF diagnostics can guide the selection of optimal antiplatelet agents, balancing efficacy and bleeding risk.
  • The clinical practice should incorporate PF diagnostics to manage patients at risk for cardiovascular events more effectively.